Parmax Pharma Ltd Adjourns Q2 Results, Backs ₹50 Crore Limits
Key highlights
- Parmax Pharma Ltd adjourned the Q2 and H1 FY27 results agenda without approving the unaudited financial statements.
- The board approved proposals for borrowing and asset-charge limits of ₹50 crore each, subject to shareholder approval.
- Parmax Pharma Ltd raised ₹19.28 crore through a preferential issue on August 28, 2026.
- The company reported no deviation in preferential-issue fund utilisation for Q2 FY27.
powered by IRIS

Parmax Pharma Ltd adjourned its Q2 and H1 FY27 results agenda without approving the financial statements, while its board approved proposals to raise borrowing and asset-charge limits to ₹50 crore each. The decisions also cover a registered-office shift, an internal auditor appointment and a proposed change in preferential-issue fund use.
Know Parmax Pharma inside out
Results, valuation, peers and who's buying, in one view.
Why did Parmax Pharma Ltd adjourn its Q2 and H1 FY27 results agenda?
Parmax Pharma Ltd did not approve the unaudited financial results for the quarter and half year ended September 30, 2026, at the board meeting. The company said that the agenda relating to Q2 and H1 FY27 results was adjourned. As a result, the available disclosure does not establish that the board adopted the results at that meeting.
The results agenda had already faced a scheduling change. The board meeting was originally planned for November 13, 2026 and was moved to November 14, 2026 because of what the company described as unavoidable circumstances. The rescheduled agenda included consideration of the unaudited quarterly and half-yearly financial results as well as the proposed relocation of the registered office.
The subsequent board update shows that the financial-results item was not concluded, even though the board considered and approved several other corporate proposals. The company has not provided a further date for consideration of the deferred results agenda in the information supplied.
What proposals did the Parmax Pharma board approve?
The board approved a proposal to shift Parmax Pharma's registered office from Gujarat to Maharashtra, subject to shareholder approval. A registered-office shift between states generally requires changes to the company's constitutional documents and approvals through the prescribed corporate process.
The board also approved raising the company's borrowing limit to ₹50 crore and the limit for creating charges on assets to ₹50 crore, with the proposals subject to shareholder approval. Borrowing limits set the ceiling for debt that a company may raise under the relevant shareholder authorisation, while asset-charge authority relates to security that may be created over company assets for lenders.
In addition, the board approved the appointment of an internal auditor. The available disclosure does not name the auditor or specify the term of appointment. Internal audit arrangements are intended to support reviews of internal controls, processes and compliance within the company.
Got a follow-up? Ask IRIS
How does the preferential issue disclosure relate to the board decisions?
Parmax Pharma reported that there was no deviation in the use of proceeds from its preferential issue during Q2 FY27. The company raised ₹19.28 crore through a preferential issue of equity shares and warrants on August 28, 2026. It stated that the funds were being used for working capital and general corporate purposes in line with the original objects.
The company also said that a portion of the funds came through warrant subscription, with the remaining amount due within 18 months. This payment structure is relevant because warrant proceeds may be received in stages rather than entirely on the original allotment date.
Separately, the board approved a proposed change in the use of preferential-issue funds, subject to shareholder approval. The supplied disclosures do not provide the revised allocation or the detailed terms of the proposed change. The no-deviation statement for the quarter and the proposal to alter the use of funds address different points in time: the first reports utilisation during Q2, while the second concerns a board-approved proposal requiring shareholder consent.
What do the ₹50 crore limits mean for Parmax Pharma Ltd?
The proposed ₹50 crore borrowing and asset-charge limits would provide Parmax Pharma with shareholder-authorised capacity to borrow and secure borrowings up to those limits. The announcement does not say that the company has raised ₹50 crore of debt, entered into a new financing arrangement, or created any specific charge on assets.
For investors, the distinction is important. A borrowing-limit approval permits financing within an authorised ceiling, whereas actual borrowings, lending terms, interest costs and security arrangements would depend on later transactions and related disclosures. The supplied information does not include the company's current debt level, planned use of any future borrowings or the timing of a potential financing exercise.
The proposals are also part of a broader set of governance and operational decisions. The internal auditor appointment, proposed registered-office move and preferential-fund-use amendment indicate that the board addressed corporate matters despite postponing the financial-results agenda. However, the Q2 and H1 FY27 results remain the key unresolved item because they are necessary for an updated assessment of operating and financial performance.
What should shareholders monitor after the board meeting?
Shareholders should monitor a fresh intimation on the adjourned results agenda and the eventual release of Q2 and H1 FY27 unaudited financial statements. Until those results are approved and disclosed, the board's update does not provide a completed financial-performance announcement for the September 2026 quarter and half year.
Investors may also track shareholder notices and voting outcomes for the proposed office relocation, the ₹50 crore borrowing limit, the ₹50 crore asset-charge limit and the proposed preferential-issue fund-use change. Any later disclosure detailing the revised use of proceeds, the internal auditor's identity, or actual borrowings would add material context to the board's decisions.
Conclusion
Parmax Pharma Ltd's board adjourned approval of Q2 and H1 FY27 results while progressing several corporate proposals. The most quantifiable approvals were the proposed ₹50 crore borrowing limit and ₹50 crore asset-charge limit, alongside a planned move of the registered office from Gujarat to Maharashtra and an internal auditor appointment.
The next item to watch is the company's rescheduled consideration of the unaudited results for the period ended September 30, 2026. Investors should also watch for shareholder approval processes and fuller details of the proposed change in utilisation of preferential-issue proceeds.


